BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24768320)

  • 1. Molecular basis of mast cell disease.
    Soucie E; Brenet F; Dubreuil P
    Mol Immunol; 2015 Jan; 63(1):55-60. PubMed ID: 24768320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.
    Zorzan E; Hanssens K; Giantin M; Dacasto M; Dubreuil P
    PLoS One; 2015; 10(11):e0142450. PubMed ID: 26562302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.
    Hanssens K; Brenet F; Agopian J; Georgin-Lavialle S; Damaj G; Cabaret L; Chandesris MO; de Sepulveda P; Hermine O; Dubreuil P; Soucie E
    Haematologica; 2014 May; 99(5):830-5. PubMed ID: 24389310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
    Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
    Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Deregulated splicing machinery in myelodysplastic syndromes].
    Ogawa S
    Rinsho Ketsueki; 2012 May; 53(5):493-6. PubMed ID: 22728550
    [No Abstract]   [Full Text] [Related]  

  • 6. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
    Visconte V; Tabarroki A; Rogers HJ; Hasrouni E; Traina F; Makishima H; Hamilton BK; Liu Y; O'Keefe C; Lichtin A; Horwitz L; Sekeres MA; Hsieh FH; Tiu RV
    Haematologica; 2013 Sep; 98(9):e105-7. PubMed ID: 23831919
    [No Abstract]   [Full Text] [Related]  

  • 7. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
    Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.
    Ivanova M; Shivarov V; Pavlov I; Lilakos K; Naumova E
    Mol Diagn Ther; 2016 Feb; 20(1):27-32. PubMed ID: 26476543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of KIT Mutations in Anaphylaxis.
    Coulson E; Zhou S; Akin C
    Curr Allergy Asthma Rep; 2019 Apr; 19(6):31. PubMed ID: 31028494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.
    Soucie E; Hanssens K; Mercher T; Georgin-Lavialle S; Damaj G; Livideanu C; Chandesris MO; Acin Y; Létard S; de Sepulveda P; Hermine O; Bernard OA; Dubreuil P
    Blood; 2012 Dec; 120(24):4846-9. PubMed ID: 23074272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.
    Reszka E; Jabłońska E; Wieczorek E; Valent P; Arock M; Nilsson G; Nedoszytko B; Niedoszytko M
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
    Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
    Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
    Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
    Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
    Horny HP; Sotlar K; Sperr WR; Valent P
    J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular defects in mastocytosis: KIT and beyond KIT.
    Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
    Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
    Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL
    Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.